
    
      This study aims to evaluate the non-inferiority of abaloparatide-sMTS 300 μg compared to
      abaloparatide-SC 80 μg based on lumbar spine bone mineral density (BMD) at 12 months and to
      evaluate the safety and tolerability of abaloparatide-sMTS in the treatment of postmenopausal
      women with osteoporosis
    
  